Emyria (EMD) Q2 2025 TU earnings summary

Executive summary

• Enrolment in MDMA-assisted therapy for PTSD increased, with strong patient retention and positive outcomes.

• Ethics endorsement received for psilocybin-assisted therapy for treatment-resistant depression.

• Empax Centre selected for a sponsored psilocybin trial in cancer patients.

• Leadership changes: Greg Hutchinson became Executive Chairman; Dr. Michael Winlo transitioned to Chief Scientific Officer.

Financial highlights

• Net cash from operating activities was $206,000 for Q2 FY25.

• $2.525M raised via placement, with $1.525M completed and $1M pending shareholder approval.

• R&D Tax Incentive refund of $572,082 received after loan repayment.

• Cash and cash equivalents at quarter end were $1.551M, up from $646,000 in the previous quarter.

• Payments to related parties totaled $106,000 for the quarter.

Outlook and guidance

• Focus on scaling mental health treatment programs and expanding Empax locations across Australia.

• Advanced "hospital substitution" pilot programs with private insurers and government payers to secure sustainable funding.

• Continued development of proprietary MDMA-inspired drug candidates for PTSD, Parkinson's, and other conditions.